A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With Chemotherapy Combined With Bevacizumab
NCT ID: NCT02673710
Last Updated: 2020-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2016-03-14
2020-02-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma
NCT00442637
Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)
NCT01900717
Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin)
NCT02612077
An Observational Study of Bevacizumab in Combination With 5-FU-Based Chemotherapy in Chinese Participants With Metastatic Colorectal Cancer
NCT01319877
An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer
NCT01266564
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with metastatic colorectal cancer
Participants diagnosed with mCRC treated in first line with a combination of bevacizumab and chemotherapy for whom it is decided to continue the administration of bevacizumab beyond progression while changing CTR will be included in this study
No intervention
Besides participant reported outcomes and a muscle strength test no interventions are administered, all treatment decisions are at the discretion of the physician and will be in line with local clinical practice and labeling
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
Besides participant reported outcomes and a muscle strength test no interventions are administered, all treatment decisions are at the discretion of the physician and will be in line with local clinical practice and labeling
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women of childbearing potential have to use effective contraception during (and up to 6 months after) treatment.
* Availability of specific retrospective data at diagnosis and during 1st line treatment
Exclusion Criteria
* Dementia or another mental condition making it impossible to fill out questionnaires
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Onze Lieve Vrouwziekenhuis Aalst
Aalst, , Belgium
AZ Sint Lucas Brugge
Assebroek, , Belgium
CHIREC
Auderghem, , Belgium
Imeldaziekenhuis
Bonheiden, , Belgium
AZ KLINA
Brasschaat, , Belgium
AZ Sint Jan
Bruges, , Belgium
Institut Jules Bordet X
Brussels, , Belgium
Hospital Erasme
Brussels, , Belgium
Cliniques Universitaires St-Luc
Brussels, , Belgium
Grand Hôpital de Charleroi Notre Dame
Charleroi, , Belgium
AZ Maria Middelares
Ghent, , Belgium
Jessa Zkh (Campus Salvator)
Hasselt, , Belgium
UZ Leuven Gasthuisberg
Leuven, , Belgium
CHC MontLégia
Liège, , Belgium
CHU Sart-Tilman
Liège, , Belgium
AZ St Maarten Campus Leopoldstr
Mechelen, , Belgium
Hôpital André Vésale
Montigny-le-Tilleul, , Belgium
AZ Damiaan
Ostend, , Belgium
AZ Delta (Campus Wilgenstraat)
Roeselare, , Belgium
AZ Glorieux- vzw Werken Glorieux
Ronse, , Belgium
AZ Nikolaas (Sint Niklaas)
Sint-Niklaas, , Belgium
AZ Turnhout Sint Elisabeth
Turnhout, , Belgium
CHR de Verviers - East Belgium
Verviers, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML29985
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.